272.36
Iqvia Holdings Inc stock is traded at $272.36, with a volume of 781.93K.
It is down -2.51% in the last 24 hours and up +0.74% over the past month.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
See More
Previous Close:
$279.36
Open:
$280.5
24h Volume:
781.93K
Relative Volume:
0.60
Market Cap:
$44.83B
Revenue:
$16.63B
Net Income/Loss:
$1.39B
P/E Ratio:
33.76
EPS:
8.0674
Net Cash Flow:
$2.12B
1W Performance:
+2.44%
1M Performance:
+0.74%
6M Performance:
+67.83%
1Y Performance:
+23.51%
Iqvia Holdings Inc Stock (IQV) Company Profile
Name
Iqvia Holdings Inc
Sector
Industry
Phone
919-998-2000
Address
2400 ELLIS ROAD, DURHAM, NC
Compare IQV vs TMO, DHR, NTRA, A, IDXX
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
IQV
Iqvia Holdings Inc
|
272.36 | 44.83B | 16.63B | 1.39B | 2.12B | 8.0674 |
|
TMO
Thermo Fisher Scientific Inc
|
680.06 | 251.45B | 45.20B | 6.87B | 6.75B | 18.19 |
|
DHR
Danaher Corp
|
232.18 | 163.22B | 24.78B | 3.68B | 5.29B | 5.1743 |
|
NTRA
Natera Inc
|
401.01 | 57.80B | 2.50B | -226.32M | 71.51M | -1.6412 |
|
A
Agilent Technologies Inc
|
175.21 | 49.40B | 7.23B | 1.41B | 1.09B | 4.979 |
|
IDXX
Idexx Laboratories Inc
|
569.73 | 44.88B | 4.45B | 1.10B | 1.06B | 13.59 |
Iqvia Holdings Inc Stock (IQV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-26 | Resumed | UBS | Buy |
| Jun-17-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-09-26 | Upgrade | TD Cowen | Hold → Buy |
| Mar-06-26 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-03-26 | Initiated | RBC Capital Mkts | Outperform |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Nov-13-25 | Initiated | BMO Capital Markets | Outperform |
| Nov-03-25 | Downgrade | TD Cowen | Buy → Hold |
| Oct-29-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-09-25 | Upgrade | HSBC Securities | Hold → Buy |
| Sep-09-25 | Upgrade | Jefferies | Hold → Buy |
| Apr-25-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-10-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-03-25 | Downgrade | BTIG Research | Buy → Neutral |
| Dec-20-24 | Initiated | Stephens | Overweight |
| Oct-14-24 | Initiated | Redburn Atlantic | Buy |
| Sep-04-24 | Initiated | RBC Capital Mkts | Outperform |
| Jul-24-24 | Downgrade | Jefferies | Buy → Hold |
| Jun-06-24 | Initiated | Goldman | Buy |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Feb-15-24 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-13-24 | Initiated | BTIG Research | Buy |
| Nov-02-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Mar-17-23 | Initiated | Truist | Buy |
| Dec-06-22 | Initiated | Cowen | Outperform |
| Nov-17-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jul-15-22 | Initiated | SVB Leerink | Outperform |
| May-24-22 | Initiated | Guggenheim | Buy |
| Apr-29-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-16-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Mar-08-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Jul-07-20 | Initiated | Stephens | Equal-Weight |
| Mar-02-20 | Initiated | Deutsche Bank | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Upgrade | CFRA | Sell → Hold |
| Nov-14-19 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-21-19 | Upgrade | Mizuho | Neutral → Buy |
| May-28-19 | Initiated | SVB Leerink | Outperform |
| Jan-18-19 | Upgrade | Jefferies | Hold → Buy |
| Oct-09-18 | Initiated | UBS | Buy |
| Oct-02-18 | Reiterated | Robert W. Baird | Outperform |
| Jul-25-18 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-25-18 | Reiterated | Stifel | Buy |
| Jul-03-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Apr-13-18 | Upgrade | Goldman | Neutral → Buy |
| Mar-07-18 | Upgrade | SunTrust | Hold → Buy |
| Jan-19-18 | Initiated | Evercore ISI | Outperform |
View All
Iqvia Holdings Inc Stock (IQV) Latest News
Iqvia stock hits 52-week high at $277.80 By Investing.com - Investing.com UK
IQVIA Gears Up to Post Q3 Earnings: Here's What Investors Should Know - Yahoo Finance
Is IQVIA Holdings Inc (IQV) Overvalued After 3.3% Rally? GF Valu - GuruFocus
AxoGen (AXGN) Reports Next Week: Wall Street Expects Earnings Growth - Zacks Investment Research
IQVIA Holdings Inc. (IQV) Options Chain - Yahoo! Finance Canada
IQVIA: R&D Bookings Are Reaccelerating, But The Valuation Now Requires Execution - Seeking Alpha
IQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy? - Zacks Investment Research
IQVIA HOLDINGS INC (NYSE:IQV) Sets Up for Breakout With Strong Technical Ratings - ChartMill
Weekly Recap: IQVIA adopts Veeva CTMS enterprise-wide and Stifel $303 Buy - TradingView
IQVIA: A $34.2 Billion Backlog Does Not Guarantee Faster Earnings Growth (NYSE:IQV) - Seeking Alpha
IQVIA Holdings Inc. Common Stock (IQV) Company Profile - Pluang
IQVIA Holdings Inc (IQV) Stock Up 3.5% but GF Value Says Overval - GuruFocus
IQVIA Holdings (NYSE:IQV) Stock Price - Simply Wall Street
IQVIA Holdings Inc. (IQV) Options Chain - Yahoo! Finance Canada
IQVIA Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Stifel lifts target for IQVIA Holdings stock to USD 303.00 - ad-hoc-news.de
IQVIA Holdings (IQV) Gains as Improving Demand Environment and High Win Rates - Yahoo Finance
Deutsche Bank Adjusts IQVIA Holdings Price Target to $179 From $191 - marketscreener.com
VEEV Expands IQVIA Partnership With Clinical Operations Software Suite - Zacks Investment Research
VEEV Expands IQVIA Partnership With Clinical Operations Software Suite - TradingView
Stifel Nicolaus Adjusts IQVIA Holdings Price Target to $303 From $276 - Yahoo Finance
JPMorgan Adjusts Price Target on IQVIA Holdings to $295 From $285 - www.marketscreener.com
JPMorgan Adjusts Price Target on IQVIA Holdings to $295 From $285 - Yahoo Finance
IQVIA Holdings Inc. (IQV) Options ChainYahoo Finance - Yahoo! Finance Canada
How Could IQVIA Holdings (NYSE:IQV) Change Clinical Trial Design? - Kalkine Media
IQVIA Selects Veeva Systems Clinical Operations Applications - marketscreener.com
Four Veeva tools will be standard across IQVIA's clinical studies - Stock Titan
IQVIA Holdings Inc. (IQV) Options ChainYahoo Finance - Yahoo! Finance Canada
IQVIA Holdings Inc. R (QTS.DE) Q1 FY2025 earnings call transcript - Yahoo Finance
IQVIA Holdings’ Quarterly Earnings Preview: What You Need to Know - Yahoo Finance
IQVIA Holdings’ Quarterly Earnings Preview: What You Need to Know - inkl
Here's Why IQVIA Holdings (IQV) is a Strong Momentum Stock - Zacks Investment Research
Leerink Partners Adjusts IQVIA Holdings Price Target to $310 From $280 - www.marketscreener.com
Leerink Partners Adjusts IQVIA Holdings Price Target to $310 From $280 - Yahoo Finance
Across 50 trials, 85% of IQVIA's predictions were on target or close. - Stock Titan
Mizuho Adjusts Price Target on IQVIA Holdings to $300 From $275 - marketscreener.com
Mizuho Adjusts Price Target on IQVIA Holdings to $300 From $275 - Yahoo Finance
IQVIA Holdings Inc. R (QTS.HM) Q2 FY2026 earnings call transcript - Yahoo Finance
IQVIA Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Evercore ISI Adjusts Price Target on IQVIA Holdings to $290 From $275, Maintains Outperform Rating - marketscreener.com
Is the Market Repricing Iqvia Holdings (NYSE:IQV) Too Quickly? - Kalkine Media
IQVIA (NYSE:IQV) Bets on AI to Power Clinical Research - Kalkine Media
RBC raises target for IQVIA Holdings stock from USD 247 to USD 319 - AD HOC NEWS
A Look at IQVIA Holdings Inc (IQV) After 3.0% Gain -- GF Value $249.70 vs Price $266.09 - GuruFocus
IQVIA Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
IQVIA Holdings Inc. (IQV) stock price, news, quote and historyYahoo Finance - Yahoo Finance Singapore
Extensive Database & Solid Bookings Benefit IQVIA Amid Low Liquidity - Zacks Investment Research
Extensive Database & Solid Bookings Benefit IQVIA Amid Low Liquidity - TradingView
Judge 'Flummoxed' By Forum Claim In IQVIA's Poaching Suit - Law360
A Look at IQVIA Holdings Inc (IQV) After 3.0% Decline -- GF Value $249.48 vs Price $260.72 - GuruFocus
Iqvia Holdings Inc Stock (IQV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Iqvia Holdings Inc Stock (IQV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| JAMES G BERKSHIRE | Officer |
Sep 02 '26 |
Proposed Sale |
261.32 |
2,668 |
697,215 |
0 |
| Berkshire James G. | See Remarks |
Sep 02 '26 |
Sale |
261.33 |
2,668 |
697,228 |
10,890 |
| WALTER STAUB | Officer |
Aug 03 '26 |
Proposed Sale |
232.68 |
5,500 |
1,279,740 |
0 |
| STAUB W RICHARD | See Remarks |
Aug 03 '26 |
Sale |
232.68 |
5,500 |
1,279,740 |
13,312 |
| Patel Bhavik | See Remarks |
Jul 31 '26 |
Sale |
235.27 |
1,855 |
436,426 |
1,348 |
| BHAVIK PATEL | Officer |
Jul 31 '26 |
Proposed Sale |
235.27 |
1,855 |
436,426 |
0 |
| ARI BOUSBIB | Officer |
Jul 29 '26 |
Proposed Sale |
245.50 |
106,279 |
26,091,897 |
0 |
| ERIC SHERBET | Officer |
Jul 29 '26 |
Proposed Sale |
249.16 |
5,000 |
1,245,775 |
0 |
| Sherbet Eric | See Remarks |
Jul 29 '26 |
Sale |
249.16 |
5,000 |
1,245,800 |
20,999 |
| Cherofsky Keriann | See Remarks |
Jul 29 '26 |
Sale |
245.21 |
558 |
136,827 |
2,989 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):